Kukje Pharma Co., Ltd.

A002720

KR7002720001

Pharmaceuticals

End-of-day quote Korea S.E. Other stock markets 06:00:00 2024-05-30 pm EDT			5-day change	1st Jan Change
4,745 ^KRW	+0.74%		-1.86%	-19.85%

May. 16	Kukje Pharma Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Mar. 18	Kukje Pharma Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Kukje Pharma Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023

March 18, 2024 at 03:05 am EDT

Kukje Pharma Co., Ltd. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported sales was KRW 135,372.69 million compared to KRW 126,583.4 million a year ago. Net loss was KRW 8,415.19 million compared to net income of KRW 3,557.33 million a year ago.

Basic loss per share from continuing operations was KRW 415 compared to basic earnings per share from continuing operations of KRW 176 a year ago. Diluted loss per share from continuing operations was KRW 415 compared to diluted earnings per share from continuing operations of KRW 176 a year ago. Basic loss per share was KRW 415 compared to basic earnings per share of KRW 176 a year ago.

Latest news about Kukje Pharma Co., Ltd.

Kukje Pharma Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 15	CI
Kukje Pharma Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 18	CI
Kukje Pharma Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
Kukje Pharma Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
Kukje Pharma Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-14	CI
Kukje Pharma Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-10	CI
Kukje Pharma Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-15	CI
Kukje Pharma Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-16	CI
Kukje Pharma Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-10	CI
OncoPep, Inc. announced that it has received $11 million in funding from TERA SCIENCE Co.,LTD, Crystal Bioscience Inc., Kukje Pharma Co., Ltd.	21-12-08	CI
Kukje Pharma Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-11-12	CI
Coronavirus infects Asia stocks with exposure to China	20-01-28	RE
ASX 200 : Coronavirus infects Asia stocks with exposure to China	20-01-28	RE
Tranche Update on Kukje Pharmaceutical Industrial Co. Ltd.'s Equity Buyback Plan announced on November 2, 2016.	17-01-11	CI
Kukje Pharmaceutical Industrial Co. Ltd.'s Equity Buyback announced on November 2, 2016, has closed with 300,000 shares, representing 1.81% for KRW 1,371.73 million.	17-01-09	CI
Kukje Pharmaceutical Industrial Co. Ltd. authorizes a Buyback Plan.	16-11-01	CI
Kukje Pharmaceutical Industrial Co. Ltd. announces an Equity Buyback for 300,000 shares.	16-11-01	CI
Kukje Pharmaceutical Industrial Co. Ltd. and other buyers cancelled the acquisition of partial stake in cosmetics business from Kukje Pharmaceutical Industrial Co. Ltd.	16-06-11	CI
Kukje Pharmaceutical Industrial Co. Ltd. and other buyers agreed to acquire partial stake in cosmetics business from Kukje Pharmaceutical Industrial Co. Ltd. for KRW 2 billion.	15-06-11	CI
Kukje Pharmaceutical Industrial Co. Ltd.’s Equity Buyback announced on August 9, 1994 has expired.	15-04-01	CI
Kukje Pharmaceutical Industrial Company Limited Equity Buyback Plan Extended till September 24, 2022	12-09-23	CI

Chart Kukje Pharma Co., Ltd.

Duration

Period

More charts

Company Profile

Kukje Pharma Co., Ltd, formerly Kukje Pharma Ind. Co., Ltd, is a Korea-based company engaged in the manufacture of pharmaceuticals. The Companyâs products are finished products, such as antibiotics, other antibiotics for injection, antifungal and antiviral agents, agents for gastrointestinal tract and liver, muscle relaxants, anti-osteoporotics, corticosteroids, agents for cardiovascular and endocrine systems, ophthalmic agents, remedies for central nervous system (CNS) disorders, remedies for urinary systems, antihistamines, antitussives, cough and cold remedies, non-steroidal anti inflammatory drugs (NSAIDs), antitussive, cough and cold remedies, as well as other over-the-counter (OTC) drugs. It also provides raw materials, such as ceftriaxone sodium sterile, cefuroxime axetil, ceftezole sodium sterile, cefminox sodium sterile, cefuroxime sodium sterile and others.

Sector

Pharmaceuticals

Calendar

2024-08-12 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
KUKJE PHARMA CO., LTD.	-19.85%	69.49M
SUN PHARMACEUTICAL INDUSTRIES LTD.	+15.91%	41.97B
OTSUKA HOLDINGS CO., LTD.	+22.40%	22.34B
SANDOZ GROUP AG	+18.48%	15.25B
CIPLA LIMITED	+16.12%	14B
ZYDUS LIFESCIENCES LIMITED	+45.12%	12.06B
ONO PHARMACEUTICAL CO., LTD.	-9.58%	6.8B
THE MEDICINES COMPANY	-0.05%	6.79B
STADA ARZNEIMITTEL	-8.87%	5.73B
ASPEN PHARMACARE HOLDINGS LIMITED	+14.18%	5.49B